Esperion Therapeutics | ESPR - Selling And Administration Expenses


Esperion Therapeutics reported $39.42M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 104.9M 13.17M Mar/2026
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Geron USD 35.42M 6.24M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 173M 135M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024